Millendo Therapeutics, Inc. MLND
Set alert
1.06 +1.06 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 20.19M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.26
- Beta
- 0.48
- Short ratio
- 0.98
- Inst. own
- 37.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 2, 2021
- 50-d avg
- 18.86
- 200-d avg
- 25.14
- 1y target
- 2.00
Key statistics
- Market cap
- 20.19M
- Enterprise value
- -3.93M
- Trailing P/E
- 0.00
- Forward P/E
- -2.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.05
- EPS (TTM)
- -25.88
- Beta
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.14M
- Total cash
- 27.24M
- Total debt
- 2.46M
- Return on equity
- -81.72%
- Shares outstanding
- 19.04M
- Short % of float
- 12.77%
- 50-day average
- 18.86
- 200-day average
- 25.14
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Next earnings
Jul 2, 2021
Expected Jul 2, 2021. Consensus EPS estimate -0.36.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 2, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Nov 9, 2020 | Sep 1, 2020 | -0.41 | — | — | — |
| Aug 10, 2020 | Jun 1, 2020 | -0.50 | — | — | — |
| May 8, 2020 | Mar 1, 2020 | -0.66 | — | — | — |
| Mar 11, 2020 | Dec 1, 2019 | -0.82 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 6, 2021 | Ladenburg Thalmann | down | Buy | Neutral |
| Jan 6, 2021 | SVB Leerink | down | Outperform | Market Perform |
| Apr 7, 2020 | Oppenheimer | down | Outperform | Perform |
| Mar 25, 2020 | Citigroup | main | — | Buy |
| Aug 13, 2019 | Oppenheimer | main | — | Outperform |
| Jul 19, 2019 | Wedbush | init | — | Outperform |
About Millendo Therapeutics, Inc.
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- millendo.com
News
- 45 Biggest Movers From Yesterday
- 31 Stocks Moving In Wednesday's Mid-Day Session
- 26 Stocks Moving in Wednesday's Pre-Market Session
- Tempest and Millendo Announce Stockholder Approval of Merger
- Stocks That Hit 52-Week Lows On Friday
- MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
- Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
- MLND Stock Price Falls Over 10% Pre-Market: Why It Happened
- Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Your note
Sign in to keep a note on MLND — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDRICH RICHARD H | Director | Stock Award(Grant) | Dec 6, 2018 | 136,852 |
| COUTURIER CHRISTOPHE | Chief Financial Officer | Stock Award(Grant) | Dec 22, 2016 | 50,900 |
| DIPP MICHELLE | Chief Executive Officer | Purchase | May 31, 2016 | 0 |
| FISHER MARY | Director | Stock Award(Grant) | Dec 6, 2018 | 3,319 |
| GALLAGHER CAROL GILTNER | Director | Stock Award(Grant) | Dec 6, 2018 | 0 |
| KOZIN MARC D | Director | Stock Award(Grant) | Dec 6, 2018 | 7,740 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 9.28% | 1,766,779 | 31.80M | Mar 30, 2021 |
| Ikarian Capital, LLC | 7.08% | 1,348,021 | 24.26M | Mar 30, 2021 |
| Renaissance Technologies, LLC | 4.86% | 924,801 | 16.65M | Mar 30, 2021 |
| Monashee Investment Management LLC | 2.63% | 500,000 | 9.00M | Mar 30, 2021 |
| Citadel Advisors LLC | 2.10% | 400,539 | 7.21M | Mar 30, 2021 |
| Vanguard Group, Inc. (The) | 1.91% | 362,926 | 6.53M | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.95% | 181,671 | 3.27M | Mar 30, 2021 |
| Bridgeway Funds Inc-Small Cap Growth Fund | 0.86% | 164,300 | 2.96M | Mar 30, 2021 |
| Vanguard Total Stock Market Index Fund | 0.86% | 163,214 | 2.94M | Mar 30, 2021 |
| iShares Micro Cap ETF | 0.26% | 49,787 | 888.70K | May 30, 2021 |
| Fidelity Extended Market Index Fund | 0.25% | 48,059 | 829.02K | Apr 29, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.12% | 22,083 | 380.93K | Apr 29, 2021 |